ReviewRheumatology (Oxford, England)2017
Systemic lupus erythematosus biomarkers: the challenging quest.
Review in Rheumatology (Oxford, England), 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 49 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
49 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Elevated Urinary Neutrophil Gelatinase-Associated Lipocalin Is a Biomarker for Lupus Nephritis: A Systematic Review and Meta-Analysis.BioMed research international · 2020Pooled it
- Haplotypes of FOXP3 genetic variants are associated with susceptibility, autoantibodies, and TGF-β1 in patients with systemic lupus erythematosus.Scientific reports · 2021Trial
- Network-based machine learning to identify biomarkers for systemic lupus erythematosus.BMC biology · 2026Article
- Dysregulated soluble immune mediators and lupus-associated autoantibody specificities inform the development of immune indexes that characterise classified SLE transition and SLE disease activity.Lupus science & medicine · 2025Article
- Identification and experimental validation of glycosylation related differentially expressed genes as diagnostic biomarkers in systemic lupus erythematosus.Scientific reports · 2025Article
- Autoantibodies in Systemic Lupus Erythematosus: Diagnostic and Pathogenic Insights.Journal of clinical medicine · 2025Review
- Serum untargeted metabolomics alterations in systemic lupus erythematosus patients with elevated serum ferritin.Scientific reports · 2025Article
- Metabolic Alterations in Colombian Women with Rheumatoid Arthritis and Systemic Lupus Erythematosus Reveal Potential Lipid Biomarkers Associated with Inflammation and Cardiovascular Risk.International journal of molecular sciences · 2025Article
- VPS13C and STING expression in neuropsychiatric systemic lupus erythematosus: unveiling an unbreached territory.Lupus science & medicine · 2024Article
- Plasma proteins and inflammatory dermatoses: proteome-wide Mendelian randomization and colocalization analyses.Archives of dermatological research · 2024Article
- iTRAQ-based mass spectrometry screen to identify serum biomarkers in systemic lupus erythematosus.Lupus science & medicine · 2024Article
- Recent Advances in Biosensors for Diagnosis of Autoimmune Diseases.Sensors (Basel, Switzerland) · 2024Review
- Urinary CD163 is a marker of active kidney disease in childhood-onset lupus nephritis.Rheumatology (Oxford, England) · 2023Article
- Role of autotaxin in systemic lupus erythematosus.Frontiers in medicine · 2023Review
- The conundrum of neuropsychiatric systemic lupus erythematosus: Current and novel approaches to diagnosis.Frontiers in neurology · 2023Review
- Circulating Thrombomodulin: Release Mechanisms, Measurements, and Levels in Diseases and Medical Procedures.TH open : companion journal to thrombosis and haemostasis · 2022Review
- A Narrative Literature Review Comparing the Key Features of Musculoskeletal Involvement in Rheumatoid Arthritis and Systemic Lupus Erythematosus.Rheumatology and therapy · 2022Review
- Predicting diagnostic gene expression profiles associated with immune infiltration in patients with lupus nephritis.Frontiers in immunology · 2022Article
- Urine Soluble CD163 Is a Promising Biomarker for the Diagnosis and Evaluation of Lupus Nephritis.Frontiers in immunology · 2022Article
- Adhesion molecules: a way to understand lupus.Reumatologia · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
SLE, a multisystem heterogeneous disease, is characterized by production of antibodies to cellular components, with activation of both the innate and the adaptive immune system. Decades of investigation of blood biomarkers has resulted in incremental improvements in the understanding of SLE. Owing to the heterogeneity of immune dysregulation, no single biomarker has emerged as a surrogate for disease activity or prediction of disease. Beyond identification of surrogate biomarkers, a multitude of clinical trials have sought to inhibit elevated SLE biomarkers for therapeutic benefit. Armed with new -omics technologies, the necessary yet daunting quest to identify better surrogate biomarkers and successful therapeutics for SLE continues with tenacity.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.